Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored Antibiotic Susceptibility-guided Therapy for H. pylori
NCT04061447Completed
- Sponsor
- Kaohsiung Medical University
- Start
- Feb 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rabeprazole, amoxicillin, clarithromycin, levofloxacin and metronidazole in Helicobacter pylori infection (2 arms), sponsored by Kaohsiung Medical University. Primary endpoint: The rate of H.pylori eradication at 6 weeks. Started Feb 2016; status: completed.
02
Drugs
rabeprazoleamoxicillinclarithromycinlevofloxacinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04061447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061447.